IL190224A0 - Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients - Google Patents

Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients

Info

Publication number
IL190224A0
IL190224A0 IL190224A IL19022408A IL190224A0 IL 190224 A0 IL190224 A0 IL 190224A0 IL 190224 A IL190224 A IL 190224A IL 19022408 A IL19022408 A IL 19022408A IL 190224 A0 IL190224 A0 IL 190224A0
Authority
IL
Israel
Prior art keywords
ppar
improvement
cognitive function
gamma agonists
negative patients
Prior art date
Application number
IL190224A
Other languages
English (en)
Original Assignee
Smithkline Beecham Cork Ltd
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL190224(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Cork Ltd, Sb Pharmco Inc filed Critical Smithkline Beecham Cork Ltd
Publication of IL190224A0 publication Critical patent/IL190224A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL190224A 2005-09-22 2008-03-17 Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients IL190224A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71935305P 2005-09-22 2005-09-22
US72737705P 2005-10-17 2005-10-17
PCT/US2006/036603 WO2007038115A2 (en) 2005-09-22 2006-09-20 Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients

Publications (1)

Publication Number Publication Date
IL190224A0 true IL190224A0 (en) 2008-11-03

Family

ID=37876831

Family Applications (2)

Application Number Title Priority Date Filing Date
IL190224A IL190224A0 (en) 2005-09-22 2008-03-17 Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients
IL190217A IL190217A0 (en) 2005-09-22 2008-03-17 Combination of rosiglitazone and donepezil for improvement of cognitive function

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL190217A IL190217A0 (en) 2005-09-22 2008-03-17 Combination of rosiglitazone and donepezil for improvement of cognitive function

Country Status (16)

Country Link
US (2) US20080262047A1 (enExample)
EP (2) EP1940403A2 (enExample)
JP (2) JP2009508960A (enExample)
KR (2) KR20080058413A (enExample)
AR (2) AR055649A1 (enExample)
AU (2) AU2006295007A1 (enExample)
BR (2) BRPI0616192A2 (enExample)
CA (2) CA2623204A1 (enExample)
CR (2) CR9848A (enExample)
EA (2) EA200800879A1 (enExample)
IL (2) IL190224A0 (enExample)
MA (2) MA29871B1 (enExample)
NO (2) NO20081843L (enExample)
PE (2) PE20070618A1 (enExample)
TW (2) TW200803896A (enExample)
WO (2) WO2007038115A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
WO2009043593A1 (en) * 2007-10-05 2009-04-09 Merz Pharma Gmbh & Co. Kgaa Combination therapy using memantine and glitazones
EP2085120A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
NZ710443A (en) 2008-08-12 2019-03-29 Zinfandel Pharmaceuticals Inc Method of identifying disease risk factors
WO2010068750A2 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
BRPI1015231A2 (pt) * 2009-06-25 2018-02-20 Alcobra Ltd método para tratamento, suavização de sintomas, alívio, melhoria e prevenção de uma doença, distúrbio ou condição cognitiva
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
WO2012053016A1 (en) * 2010-10-22 2012-04-26 Cadila Healthcare Limited Sustained release pharmaceutical compositions of donepezil
MX358594B (es) * 2011-01-10 2018-08-27 Zinfandel Pharmaceuticals Inc Factores de riesgo de enfermedad y métodos de uso.
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
US9907789B2 (en) 2011-10-21 2018-03-06 Takeda Pharmaceutical Company Limited Sustained-release preparation
US20140294724A1 (en) * 2011-10-24 2014-10-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
WO2014171542A1 (ja) * 2013-04-19 2014-10-23 武田薬品工業株式会社 放出制御製剤
AU2017301596A1 (en) * 2016-07-26 2019-02-07 Ausio Pharmaceuticals, Llc Methods of diagnosing and treating Alzheimer's disease with S-equol
US20180153859A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI951701L (fi) * 1992-10-13 1995-04-10 Univ Duke Menetelmät Alzheimerin taudin tunnistamiseksi
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
DE69942672D1 (de) * 1998-12-17 2010-09-23 Mindset Biopharmaceuticals Usa Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns
WO2005074917A1 (en) * 2004-01-30 2005-08-18 Axonyx, Inc. Methods for treatment of complications of diabetes

Also Published As

Publication number Publication date
BRPI0616192A2 (pt) 2011-06-14
CR9848A (es) 2008-06-18
AU2006295007A1 (en) 2007-04-05
WO2007038112A2 (en) 2007-04-05
EP1940403A2 (en) 2008-07-09
JP2009508960A (ja) 2009-03-05
NO20081847L (no) 2008-06-18
BRPI0616100A2 (pt) 2011-06-07
US20080226719A1 (en) 2008-09-18
AR056527A1 (es) 2007-10-10
KR20080056731A (ko) 2008-06-23
KR20080058413A (ko) 2008-06-25
TW200803896A (en) 2008-01-16
EA200800880A1 (ru) 2009-02-27
IL190217A0 (en) 2008-11-03
MA29872B1 (fr) 2008-10-03
JP2009508959A (ja) 2009-03-05
PE20070618A1 (es) 2007-07-04
CA2623210A1 (en) 2007-04-05
EA200800879A1 (ru) 2008-10-30
CR9849A (es) 2008-05-21
AR055649A1 (es) 2007-08-29
MA29871B1 (fr) 2008-10-03
US20080262047A1 (en) 2008-10-23
CA2623204A1 (en) 2007-04-05
WO2007038112A3 (en) 2007-12-06
PE20070976A1 (es) 2007-12-05
EP1926488A2 (en) 2008-06-04
NO20081843L (no) 2008-06-16
TW200803851A (en) 2008-01-16
WO2007038115A2 (en) 2007-04-05
AU2006295010A1 (en) 2007-04-05
WO2007038115A3 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
IL190224A0 (en) Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients
PL1948219T3 (pl) Analogi VEGF i sposoby ich stosowania
EP2037468A4 (en) ADDITIVE FOR ELECTROLYTIC SOLUTION AND ELECTROLYTIC SOLUTION
ZA200802501B (en) Indenoisoquinolinone analogs and methods of use thereof
GB0616376D0 (en) Raman analysis of tissue
PL1701150T3 (pl) Liczenie białych krwinek
IL178564A0 (en) Improved modulators of coagulation factors
AU304209S (en) Laryngoscope
EP1955271A4 (en) PRODUCTS AND METHODS FOR MANAGING FINANCIAL INSTRUMENTS RELATED TO LIFE
GB0525936D0 (en) Methods of analysing apparatus
IL212364A0 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
GB0724202D0 (en) Battery life monitor
GB0724200D0 (en) Battery life monitor
EP1857494A4 (en) HYDROGEL FOR MEDICAL USE
DK2392335T3 (en) Use of 24-norUDCA
ZA200904465B (en) Condom holder
ZA200802438B (en) PPAR-Gamma agonists for improvement of cognitive function in APOE4 negative patients
GB0510877D0 (en) Battery monitor
IL179567A0 (en) Device and method for in-vivo illumination
EP1951218A4 (en) MEDICAMENT FOR USE IN CONNECTION WITH CARTILAGE REMOVAL
HK1117384A (en) Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients
GB0504209D0 (en) New use of PDE7 inhibitors
TWI366941B (en) Electrolyte containing oxocarbons and its use
GB0621749D0 (en) Novel removable total contact cast
TWM292198U (en) Battery holder